Bioblast Pharma Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Public, Subsidiary
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://bioblast-pharma.com
Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Bioblast Pharma Ltd.
- Registration Number
- NCT04226924
- Locations
- 🇨🇦
Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada
🇨🇦Ecogene-21, Chicoutimi, Quebec, Canada
🇨🇦CHU de Québec-Université Laval- Hôpital Enfant-Jésus, Québec, Quebec, Canada
A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer Subjects
- Interventions
- Drug: Saline 0.9% IV
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02725957
- Locations
- 🇺🇸
PAREXEL Baltimore Early Phase Clinical Unit; Harbor Hospital, Baltimore, Maryland, United States
Continuation Protocol to Protocol BBCO-001
Phase 3
Completed
- Conditions
- Muscular Dystrophy, Oculopharyngeal (OPMD)
- Interventions
- Drug: Tehalose 30gr
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT02328482
- Locations
- 🇨🇦
Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease
Phase 2
Completed
- Conditions
- Machado-Joseph Disease / Spinocerebellar Ataxia 3
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT02147886
- Locations
- 🇮🇱
Meir Medical Center, Kfar Saba, Israel
Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Bioblast Pharma Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02015481
- Locations
- 🇨🇦
Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
🇺🇸UCLA, Los Angeles, California, United States
🇮🇱Hadassah medical center, Jerusalem, Israel
© Copyright 2025. All Rights Reserved by MedPath